Clinical trial · Interventional
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
NCT02943590CI-TRIAL-00089725completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called "statins"
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Heart Failure | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atorvastatin | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
- interventionNames
- Drug: Placebo
- type
- EXPERIMENTAL
- label
- Atorvastatin
- description
- Atorvastatin will be administered at a pre determined dose The drug is taken by mouth, once a day (evening)
- interventionNames
- Drug: Atorvastatin
Primary outcomes (1)
- measure
- The Percentage of Individuals in Each Group With a Significant Decline in the LVEF.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years of age * All patients with newly diagnosed NHL and HL * Scheduled to receive anthracycline-based therapy Exclusion Criteria: * Statin use or Statin use is indicated based on guidelines * Pregnancy or breastfeeding * Unable to provide informed consent * Unexplained persistent elevation of transaminases (\>3 times upper limits of normal) * Concomitant use of cyclosporine * Renal failure: estimated glomerular filtration \<45 mL/min/1.73 m2 * Contraindication to a CMR (metallic object, severe claustrophobia, pacemaker, vascular clip * LVEF of \<50% at baseline
References
Publications (6)
- DERIVEDJuhasz V, Quinaglia T, Drobni ZD, Gilman HK, Heemelaar JC, Neuberg DS, Han Y, Ky B, Kwong RY, Januzzi JL, Asnani A, Redd RA, Mousavi N, Jerosch-Herold M, Scherrer-Crosbie M, Neilan TG. Atorvastatin and left ventricular strain during anthracycline-based chemotherapy. Int J Cardiol. 2026 Jul 1;454:134439. doi: 10.1016/j.ijcard.2026.134439. Epub 2026 Mar 22. PMID 41875954
- DERIVEDJuhasz V, Drobni ZD, Quinaglia T, Gilman HK, Brendel JM, Suero-Abreu GA, Ghamari A, Heemelaar JC, Neuberg DS, Han Y, Ky B, Kwong RY, Januzzi JL, Asnani A, Mousavi N, Redd RA, Jerosch-Herold M, Scherrer-Crosbie M, Neilan TG. Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2026 Jan 1;11(1):68-76. doi: 10.1001/jamacardio.2025.4548. PMID 41205202
- DERIVEDJuhasz V, Drobni ZD, Quinaglia T, Gilman HK, Suero-Abreu GA, Ghamari A, Heemelaar JC, Neuberg DS, Han Y, Ky B, Kwong RY, Januzzi JL, Asnani A, Mousavi N, Redd RA, Jerosch-Herold M, Scherrer-Crosbie M, Neilan TG. Atorvastatin and left atrial function during anthracycline-based chemotherapy. J Cardiovasc Magn Reson. 2025 Winter;27(2):101946. doi: 10.1016/j.jocmr.2025.101946. Epub 2025 Aug 26. PMID 40876541
- DERIVEDJuhasz V, Quinaglia T, Drobni ZD, Heemelaar JC, Neuberg DS, Han Y, Ky B, Kwong RY, Januzzi JL, Asnani A, Redd RA, Mousavi N, Jerosch-Herold M, Scherrer-Crosbie M, Neilan TG. Atorvastatin and Myocardial Extracellular Volume Expansion During Anthracycline-Based Chemotherapy. JACC CardioOncol. 2025 Feb;7(2):125-137. doi: 10.1016/j.jaccao.2024.11.008. Epub 2025 Jan 28. PMID 39967198
- DERIVEDNemec R, Scherrer-Crosbie M, Abramson JS, Redd R, Gilman HK, Ho T, Wu J, Heemelaar J, Neuberg D, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Friedman RS, LaCasce AS, Neilan TG, Soumerai JD. Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP. Leuk Lymphoma. 2024 Jun;65(6):783-788. doi: 10.1080/10428194.2024.2317343. Epub 2024 Feb 21. PMID 38380861